acetylcholinesterase inhibitors (ACHEIs)
Progress in mechanisms of acetylcholinesterase inhibitors and memantine for treatment of Alzheimer’s disease
... Alzheimer’s disease (AD) is the most common causes of dementia in the elderly. Currently, only two classes of drugs, acetylcholinesterase inhibitors (AChEIs) and memantine are approved. AChEIs ameliorate ...
7
Tolerability of atypical neuroleptics and acetylcholinesterase inhibitors when treating neuropsychiatric symptoms in Parkinson's disease
... In summary, we feel that our study demonstrates effectively that rivastigmine, donepezil, memantine, quetiapine, and clozapine were well tolerated in treating the neuropsychiatric symptoms of PD. Our results support ...
7
“3D QSAR and In Silico Docking Studies of Natural Flavonoid Derivatives as Acetylcholinesterase Inhibitors” by Shravan Kumar Gunda, Suchitra pasula, Venu Gurram, Mahmood Shaik, India.
... as Acetylcholinesterase inhibitors (training set 46 molecules, test set 7 ...the inhibitors into the active site of the acetyl-cholinesterase enzyme and these docking studies revealed the vital ...
8
Synthesis, molecular docking and design of Tetrahydroquinolines as acetylcholinesterase inhibitors
... the acetylcholinesterase enzyme (AChE) [12] and its action as a partial NMDA receptor ...disease. Acetylcholinesterase inhibitors (AChEI) also have many other pharmacological applications; for ...
8
Possibility of Acetylcholinesterase Overexpression in Alzheimer Disease Patients after Therapy with Acetylcholinesterase Inhibitors
... Summary: Acetylcholinesterase is an enzyme responsible for termination of excitatory transmission at cholinergic synapses by the hydrolyzing of a neurotransmitter ...of acetylcholinesterase in the organism ...
6
Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors
... of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer’s disease, have generally focused on overall cognitive ...of acetylcholinesterase inhibitors on ...
8
QSAR analysis on tacrine-related acetylcholinesterase inhibitors
... In this work, we present ten useful structure-activity models to analyze the activity of Acetylcholinesterase inhibitors. The proposed QSAR models highlight paral- lelisms between the molecular structure ...
8
Discovery of Potent Carbonic Anhydrase and Acetylcholinesterase Inhibitors: 2-Aminoindan β-Lactam Derivatives
... Author Contributions: Mustafa Zengin and İlhami Gülçin were responsible for the majority of this work, including the execution of experiments, data analysis, and writing and publication of this report; Hayriye Genç ...
13
A prescription survey about combined use of acetylcholinesterase inhibitors and anticholinergic medicines in the dementia outpatient using electronic medication history data from community pharmacies
... an acetylcholinesterase inhibitor (AChEI) that increases acetylcholine (ACh) levels and can compete against anti- cholinergics in terms of its pharmacologic ...
9
Synthesis and Biological Evaluation of 1,3-Indandione Derivatives as Acetylcholinesterase Inhibitors
... The synthesis and activity of 1,3-indandione derivatives as acetylcholinesterase (AChE) inhibitors are reported. The synthetic key- step consists of the Knovenagel olefination between 1,3-indandione and a ...
14
Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?
... AchEIS: Acetylcholinesterase inhibitors; AFFIRM: Natalizumab safety and efficacy in relapsing remitting multiple sclerosis; BRNB: Brief repeatable neuropsychological battery; CI: Cognitive impairment; CII: ...
7
Synthesis, in Vitro Pharmacology, and Molecular Modeling of Very Potent Tacrine−Huperzine A Hybrids as Acetylcholinesterase Inhibitors of Potential Interest for the Treatment of Alzheimer's Disease
... enzyme, inhibitors, and the enzyme - inhibitor complexes are described by their predominant con- formational and ionization states, and that entropy contribu- tions are roughly the same for the different binding ...
16
New Tacrine−Huperzine A Hybrids (Huprines): Highly Potent Tight Binding Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer's Disease
... AChE inhibitors of increased potency and selectivity, able to bind simul- taneously to the catalytic and peripheral sites of AChE and not only to the catalytic site as is the case for the above-cited ...
10
“In silico Approach for Validation of Maltol Derivatives as Acetylcholinesterase Inhibitors” by Kuna Yellamma, Punabaka Jyothi, India.
... In silico molecular docking approach, through screening of chemical libraries to the active site of the target protein is playing a vital role in identification of lead molecules. Prediction of drug properties and ...
7
Progression of intervention-focused research for Gulf War illness
... against acetylcholinesterase (AChE) [1, ...these acetylcholinesterase inhibitors (AChEIs) may lead to the manifestation of symptoms arising from dysfunction of central and peripheral cho- linergic ...
17
The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies
... randomizing the data using the Fischer’s randomization test. Then, a test set of 26 diverse compounds with AChE inhibitory activity was selected to validate the best pharmacophore model. The test set covers similar ...
13
Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s disease
... therapeutic acetylcholinesterase inhibitors (AChEIs) can facilitate cholinergic transmission, interfere with the syn- thesis, deposition and aggregation of toxic Aβ-peptides [32, ...
57
Caregivers’ perspectives and experiences of withdrawing acetylcholinesterase inhibitors and memantine in advanced dementia: a qualitative analysis of an online discussion forum
... cholinesterase inhibitors (ChEIs), donepezil, rivastigmine and galanta- mine, are the pharmacological agents of choice for the treatment of mild to moderate Alzheimer’s disease [6], and rivastigmine is licensed ...
10
<em>FOXO1</em> locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer’s disease
... In the analysis, we observed a significant association of rs7981045 G/G with a poor response to AChEI treatment and important differences in LD coefficient values[r] ...
9
Virtual Screening of Solanine and its derivatives to analyze inhibitory activity towards Acetylcholinesterase for the treatment of Alzheimer’s disease
... 2010). Acetylcholinesterase inhibitors are the standard of therapy and are the only class of drugs approved by the Food and Drug Administration (FDA) to treat AD patients (Cummings JL, ...to ...
14